AUS
NZ
UK
CA
USA
IND
Highlights
- Wellnex Life (WNX) secures $14.3M for London Stock Exchange dual listing.
- The move aims to strengthen financials, reduce debt, and expand European market reach.
- Capital raise supports Pain Away acquisition, fueling strong revenue growth.
Wellnex Life (ASX:WNX) is gearing up for a major milestone with a planned dual listing on the London Stock Exchange’s Alternative Investment Market (AIM). The company has successfully secured conditional binding commitments amounting to $14.3 million, which will support this initiative.
The listing is expected to provide broader market exposure, strengthen financial stability, and drive international expansion. The capital raise has attracted interest from institutional and sophisticated investors across both Australia and the UK, signaling strong confidence in Wellnex’s growth potential.
The fundraising involves a non-renounceable pro-rata entitlement offer, allowing eligible shareholders to subscribe for one new share per existing share at an issue price of $0.65. Investors can also apply for additional shares in cases where some shareholders do not fully utilize their entitlement or are restricted by geographical constraints.
Capital Boost and Market Expansion
This dual listing is expected to bring multiple financial and strategic benefits. Wellnex anticipates a cost saving of approximately $1.4 million by eliminating $12.8 million in debt through the raised funds. Additionally, the listing on AIM will enhance the company’s credibility and visibility as it enters the European market with its consumer healthcare brands.
The initiative remains subject to regulatory approvals and the completion of the conditional capital raise. If successful, this move will grant Wellnex access to a wider investor base familiar with the consumer healthcare sector, allowing it to tap into deeper capital pools.
Strengthening the Business with Pain Away
A portion of the raised capital will also be directed toward completing the payment for Wellnex’s acquisition of Pain Away, a leading Australian topical pain relief brand. The acquisition, finalized in December 2023, has already played a key role in reshaping the company’s financial performance.
Pain Away’s diverse product lineup—comprising creams, sprays, patches, lotions, and tablets—has witnessed significant traction, generating record revenues exceeding $3 million in November and December 2024. The brand is widely available in more than 6,000 pharmacy and grocery outlets across Australia, reinforcing Wellnex’s position in the healthcare sector.
With a strengthened balance sheet and an expanded market presence, Wellnex is positioning itself for long-term growth, leveraging new opportunities both domestically and internationally. The upcoming dual listing could mark a transformative phase, aligning the company with some of the biggest names in the global healthcare industry.
